Sanofi and Clayton, Dubilier & Rice (CD&R) announced exclusive negotiations for the transfer of a 50% controlling stake in Opella, Sanofi's consumer healthcare division. With this partnership, Opella is set to embark on a bold new phase of growth, fueled by CD&R’s expertise and Sanofi’s continued support as a significant shareholder. Together, they aim to transform Opella into a global consumer healthcare leader.

Opella, which operates in over 100 countries and employs more than 11,000 people, is poised to leverage its portfolio of iconic brands—such as Allegra, Doliprane, and Dulcolax—and capitalize on growing health and wellness trends. This strategic move aligns with Sanofi’s ongoing focus on becoming a science-driven biopharma company delivering innovative medicines and vaccines.

Sanofi’s 2024 business earnings per share (EPS) guidance has been upgraded in line with this development.

Opella’s Journey to Global Leadership
As one of the top three players in the over-the-counter (OTC) and vitamins, minerals & supplements (VMS) markets, Opella is well-positioned to grow in the rapidly expanding consumer healthcare sector. With 13 strategic manufacturing sites and four innovation hubs, the company serves more than half a billion consumers worldwide. The joint investment by CD&R and Sanofi will enable Opella to further expand its global footprint and enhance its market leadership in the consumer healthcare space.

Paul Hudson, CEO of Sanofi, commented:
“We are incredibly proud of Opella’s success and the dedication of its people. This partnership with CD&R will enable Opella to scale new heights, while allowing Sanofi to concentrate on its mission to bring innovative solutions to patients. We are confident that Opella will thrive as an independent company underpinned by its talented team and global reach.”

Eric Rouzier, Partner and Head of European Healthcare at CD&R, said:
“Opella is a powerful player in consumer healthcare, and we see tremendous potential to accelerate its growth. We look forward to partnering with Sanofi to support Opella’s ambitious vision and development.”

A New Chapter for Sanofi
This move will allow Sanofi to sharpen its focus on delivering groundbreaking treatments in key therapeutic areas such as respiratory syncytial virus (RSV), chronic obstructive pulmonary disease (COPD), and multiple sclerosis. Sanofi will maintain a strong interest in Opella’s growth, retaining a significant minority share.

The transaction, based on an enterprise value of approximately €16 billion, is expected to close by Q2 2025, subject to final agreements and regulatory approvals.